Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 26Prostatic Neoplasms 24Breast Neoplasms 23Leukemia, Myeloid, Acute 20Carcinoma, Non-Small-Cell Lung 20Lymphoma 19Melanoma 16Lymphoma, Non-Hodgkin 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Colorectal Neoplasms 12Wilms Tumor 11Myelodysplastic Syndromes 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Lung Neoplasms 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Sarcoma, Ewing 7Osteosarcoma 7Neuroectodermal Tumors, Primitive, Peripheral 7

Interventions

ruxolitinib 1idecabtagene vicleucel 1fludarabine 1Leukapheresis 1Lenalidomide 1Cyclophosphamide 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hematologic Diseases × 30 days × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡